Lilly Foundayo + LillyDirect Telehealth Stack: 35% of Launch Volume via Mid-Channel Distribution Per Q1 Commentary
Eli Lilly executives' Q1 commentary clarified the Foundayo launch-channel mix: roughly 45% via LillyDirect (the company's direct-to-patient pharmacy), 35% via telehealth platforms not captured in retail-only IQVIA data, and 20% via traditional retail pharmacy fills. The split helps explain the apparent gap between Citi's IQVIA-reported 10,248 Week 5 prescriptions and the 20,000+ patient count Lilly disclosed on the April 30 Q1 call. The pattern suggests Foundayo is being adopted preferentially through digitally-enabled care channels — Hims & Hers, LifeMD, JoinFound, and other telehealth platforms with weight-management Rx infrastructure — rather than primary-care prescribing. The mix is structurally similar to the Wegovy pill launch but with a higher telehealth share. The implication for the next 90 days: PBM coverage expansion (mid-May) and brand-name TV advertising (launching late May per the Q1 commentary) will drive most of the next leg of growth.